What the bad jobs report means for markets
Fernando M. Rodrigues, the President of BetterHelp, a subsidiary of Teladoc Health, Inc. (NYSE:TDOC), has recently sold shares in the company. The sale comes at a time when InvestingPro data shows the stock has faced challenges, with poor performance over the last month and ongoing profitability concerns. According to a filing with the Securities and Exchange Commission, Rodrigues sold 3,558 shares of Teladoc Health common stock on March 5, 2025, at a price of $9.20 per share. The total value of the transaction amounted to $32,733. While the company operates with a moderate level of debt, InvestingPro analysis indicates a strong free cash flow yield, suggesting potential value despite current market challenges. Discover more insights with InvestingPro’s comprehensive research report, available along with 6 additional ProTips for TDOC.
The transaction was executed under a pre-established Rule 10b5-1 trading plan, which Rodrigues adopted in November 2024 and later amended. Following this sale, Rodrigues no longer holds any shares in Teladoc Health directly. The company currently trades at a high EBITDA multiple and analysts do not anticipate profitability this year, according to InvestingPro data.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $640.5 million, slightly above the forecast of $638.5 million. However, the company missed earnings per share (EPS) expectations, reporting -$0.28 compared to the anticipated -$0.23. The full-year revenue for 2024 was $2.6 billion, marking a 1% decrease from the previous year. Teladoc’s stock experienced a decline following these earnings results, reflecting investor concerns over the earnings miss and future guidance. The company recently announced a partnership with Gifthealth, Eli Lilly (NYSE:LLY)’s LillyDirect pharmacy partner, to enhance access to the FDA-approved medication Zepbound (tirzepatide) for its Comprehensive Weight Care Program. This collaboration aims to improve medication availability for members lacking insurance coverage for GLP-1s for obesity. Analysts from Truist and Stifel maintained their Hold ratings on Teladoc, with price targets of $10 and $9, respectively, following these developments. Stifel noted that Teladoc’s guidance for 2025 did not meet market consensus, attributing this to challenges such as the loss of a significant client and foreign exchange headwinds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.